KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Gross Profit (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Gross Profit for 12 consecutive years, with $252.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Profit rose 248.86% year-over-year to $252.0 million, compared with a TTM value of $480.4 million through Dec 2025, up 113.1%, and an annual FY2025 reading of $480.4 million, up 113.1% over the prior year.
  • Gross Profit was $252.0 million for Q4 2025 at Travere Therapeutics, up from $38.4 million in the prior quarter.
  • Across five years, Gross Profit topped out at $252.0 million in Q4 2025 and bottomed at -$157.2 million in Q4 2021.
  • Average Gross Profit over 5 years is $46.9 million, with a median of $40.2 million recorded in 2023.
  • The sharpest move saw Gross Profit crashed 421.34% in 2021, then soared 248.86% in 2025.
  • Year by year, Gross Profit stood at -$157.2 million in 2021, then soared by 118.11% to $28.5 million in 2022, then surged by 42.23% to $40.5 million in 2023, then soared by 78.38% to $72.2 million in 2024, then skyrocketed by 248.86% to $252.0 million in 2025.
  • Business Quant data shows Gross Profit for TVTX at $252.0 million in Q4 2025, $38.4 million in Q3 2025, and $112.9 million in Q2 2025.